Integra Lifesciences Holding (IART) — Institutional Investor Activity (Q2 2026)

IART ranks #2849 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

214 institutions disclose a position in IART, but none treat it as a major bet — even Access Investment Management LLC, its most concentrated holder, allocates just 1.9% of its own portfolio to it.

IART is down 2.4% today, but institutions show net buying of $68.3M this quarter — a divergence between today's price move and the underlying institutional flow.

IART reported a net loss of $7.2M over the trailing twelve months.

• Not yet profitable — net loss of $7.2M over the trailing twelve months
• Revenue grew 1.6% year over year
• Net income improved year over year, from -$500.6M to -$7.2M
• Generated $50.4M in positive operating cash flow
• Current ratio of 2.54x — enough short-term assets to cover short-term liabilities
• Liabilities run 2.45x equity — a highly leveraged balance sheet worth noting